Moderna, Inc. (NASDAQ:MRNA) Stake Raised by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 12.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,629,865 shares of the company’s stock after acquiring an additional 285,662 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.68% of Moderna worth $74,557,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MRNA. Voloridge Investment Management LLC raised its holdings in Moderna by 335.6% during the 4th quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company’s stock worth $107,727,000 after buying an additional 1,996,003 shares during the period. Deutsche Bank AG raised its holdings in Moderna by 54.7% during the 4th quarter. Deutsche Bank AG now owns 1,894,075 shares of the company’s stock worth $78,756,000 after buying an additional 669,614 shares during the period. TB Alternative Assets Ltd. acquired a new stake in Moderna during the 1st quarter worth about $18,495,000. Federated Hermes Inc. raised its holdings in Moderna by 152,061.1% during the 1st quarter. Federated Hermes Inc. now owns 617,774 shares of the company’s stock worth $17,514,000 after buying an additional 617,368 shares during the period. Finally, Bridgewater Associates LP acquired a new stake in Moderna during the 4th quarter worth about $25,188,000. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

MRNA has been the topic of several recent analyst reports. Bank of America cut their price objective on Moderna from $26.00 to $25.00 and set an “underperform” rating on the stock in a report on Tuesday, July 22nd. Barclays lowered their target price on Moderna from $40.00 to $31.00 and set an “equal weight” rating on the stock in a research note on Monday, August 4th. Morgan Stanley reaffirmed an “equal weight” rating and set a $32.00 target price on shares of Moderna in a research note on Friday, August 1st. Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Moderna in a research note on Sunday, July 13th. Finally, William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Monday, June 2nd. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $43.59.

Moderna Stock Up 4.8%

Shares of Moderna stock opened at $26.89 on Thursday. The stock has a market capitalization of $10.46 billion, a P/E ratio of -3.57 and a beta of 1.83. The stock has a 50 day moving average price of $29.18 and a two-hundred day moving average price of $29.73. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $91.99.

Moderna (NASDAQ:MRNA) last announced its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.99) by $0.86. The firm had revenue of $142.00 million during the quarter, compared to analysts’ expectations of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%. The company’s revenue was down 41.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($3.33) earnings per share. Sell-side analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.